PMID- 31612597
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20221207
IS  - 1365-2982 (Electronic)
IS  - 1350-1925 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Feb
TI  - Effects of acotiamide on functional dyspepsia patients with heartburn who failed 
      proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, 
      placebo-controlled crossover study.
PG  - e13749
LID - 10.1111/nmo.13749 [doi]
AB  - BACKGROUND: Functional dyspepsia (FD) and non-erosive reflux disease (NERD) are 
      gastrointestinal disorders that often overlap. In this randomized, double-blind, 
      placebo-controlled crossover study, the effects of adding acotiamide to treatment 
      with proton pump inhibitors (PPI) were investigated in FD patients with heartburn 
      who failed PPI treatment, corresponding to PPI-resistant NERD. METHODS: The 
      subjects included 16 FD patients with heartburn who failed PPI treatment, and 
      they were administered acotiamide or a placebo for 28 days. After suspending 
      medication for 28 days, the trial drug and placebo were crossed over and 
      administered for 28 days. Before the study began and after each administration 
      period, high-resolution impedance manometry (HRiM) was performed, and the 
      modified frequency scale for the symptoms of gastroesophageal reflux disease 
      (FSSG) questionnaire was administered. KEY RESULTS: Postprandial fullness in the 
      FD assessment and all modified FSSG items were significantly lower in the 
      acotiamide group than in the placebo group. Esophagogastric junction pressure was 
      significantly higher in the acotiamide group. The distal contractile integral 
      (DCI) pressure and the highest DCI pressure both increased significantly in the 
      acotiamide group. Moreover, in the acotiamide group, the frequency of abnormal 
      primary peristalsis decreased to normal levels; complete bolus transit (CBT), an 
      indicator of esophageal clearance, increased; and CBT time decreased. CONCLUSIONS 
      & INFERENCES: Acotiamide was considered to improve upper gastrointestinal 
      functions not only in the stomach but also in the esophagus. Adding acotiamide to 
      PPI therapy appears to improve upper abdominal symptoms in FD patients with 
      heartburn who failed PPI treatment.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Funaki, Yasushi
AU  - Funaki Y
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Ogasawara, Naotaka
AU  - Ogasawara N
AUID- ORCID: 0000-0002-7762-8512
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Kawamura, Yurika
AU  - Kawamura Y
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Yoshimine, Takashi
AU  - Yoshimine T
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Tamura, Yasuhiro
AU  - Tamura Y
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Izawa, Shinya
AU  - Izawa S
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Ebi, Masahide
AU  - Ebi M
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Sasaki, Makoto
AU  - Sasaki M
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
FAU - Kasugai, Kunio
AU  - Kasugai K
AD  - Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20191015
PL  - England
TA  - Neurogastroenterol Motil
JT  - Neurogastroenterology and motility
JID - 9432572
RN  - 0 (Benzamides)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Thiazoles)
RN  - D42OWK5383 (Z 338)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People
MH  - Benzamides/*therapeutic use
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Dyspepsia/*drug therapy
MH  - Female
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Gastrointestinal Diseases/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thiazoles/*therapeutic use
OTO - NOTNLM
OT  - acotiamide
OT  - esophageal motility
OT  - functional dyspepsia
OT  - gastroesophageal reflux disease
OT  - manometry
EDAT- 2019/10/16 06:00
MHDA- 2021/02/11 06:00
CRDT- 2019/10/16 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/09/19 00:00 [revised]
PHST- 2019/09/27 00:00 [accepted]
PHST- 2019/10/16 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2019/10/16 06:00 [entrez]
AID - 10.1111/nmo.13749 [doi]
PST - ppublish
SO  - Neurogastroenterol Motil. 2020 Feb;32(2):e13749. doi: 10.1111/nmo.13749. Epub 
      2019 Oct 15.